Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




China to Expand Neonatal Screening

By Labmedica staff writers
Posted on 07 Aug 2006
PerkinElmer Wallac Inc. More...
(Turku, Finland) has signed a five-year agreement with the Ministry of Health of the People's Republic of China (Bejing), to help expand neonatal screening for genetic diseases in seven of China's least economically developed provinces.

The program, which begins this year, is part of the Chinese Ministry of Health's Sino-Finnish neonatal screening cooperation program.

Under the terms of the five-year agreement, the Chinese Ministry of Health will purchase assay kits that will be used on the Victor multilabel plate readers donated by PerkinElmer for genetic testing. As a result, labs will have a powerful system for the detection and direct quantification of DNA and proteins. This is the second neonatal screening program between the Chinese Ministry of Health and PerkinElmer, a provider of neonatal screening technology. In the first program, initiated in 1996, PerkinElmer donated five neonatal screening systems and ran a neonatal educational program in China.

From now until the end of 2006, the implementation plans will be mapped out. During the years 2007-2009, training courses and information seminars will take place, and in the year 2010 a final assessment of the cooperation will be made.

Sources from the Ministry of Health said that neonatal disease screening began in the early 1980s in China. After implementation of laws and regulations to improve the health quality of newborn babies, hospitals started to screen babies for hypothyroidism (CH) and phenylketonuria (PKU). However, neonatal screening is still unsatisfactory in some urban and less-developed areas.

In 2005, PerkinElmer systems were used to screen more than 50% of the four million babies who received newborn screenings in China. This expanded initiative will enable China's Ministry of Health to increase the screening rate by at least 30% annually in each of the seven provinces involved: Hubei, Heilongjiang, Liaoning, Guangxi, Shanxi, Qinghai, and Guizhou. In addition to screening, the enhanced program will provide health education to physicians and lab staff at local screening centers, thereby improving the knowledge of genetic diseases and developing technical skills.

"As part of our ongoing commitment to newborn screening and maternal health worldwide, we are pleased to be supporting China's Ministry of Health once again with this neonatal screening effort,” said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences. "We are particularly excited that this partnership will reach families in seven of China's most underserved provinces, helping to reduce neonatal morbidity and mortality.”



Related Links:
PerkinElmer Wallac

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.